UNIVERSITÀ DEGLI STUDI DI TORINO

CURRICULUM VITAE

Francesco Ceci

Personal Information

Name: Francesco

Surname: Ceci

Date of birth: November 25th 1983

Business address: Nuclear Medicine, AOU Città della Salute e della Scienza di Torino, Corso AM Dogliotti 14, 10126 Turin, Italy

Telephone: +39 011 6335024;

E-mail: francesco.ceci@unito.it

Scopus ID: 55769083100

ORCID: 0000-0001-9785-5248

Researcher ID: L-2605-2016

Education

2002: Scientific High School Diploma (score: 100/100).

2002 – 2009: School of Medicine - Alma Mater Studiorum University of Bologna.
Medical Doctor (MD), graduated magna cum laude (score: 110/110 *cum laude*; date: January 18th 2010).
Dissertation/Thesis title: ^{18}F-FDG small animal PET study of Sorafenib efficacy in lymphoma preclinical models (Supervisor: prof. Stefano Fanti).
2010: License to practice (score: 264,75/270; date July 23rd 2010).

2011 – 2016: Nuclear Medicine Residency Program – Alma Mater Studiorum University of Bologna. Board Certified in Nuclear Medicine (score: 110/110 *cum laude*; date: July 5th 2016). Dissertation/Thesis title: ^{68}Ga-PSMA PET/CT for restaging prostate cancer in patients who experienced biochemical relapse after radical therapy.

2016 - 2019: PhD in Surgical Sciences (Urology) at Alma Mater Studiorum University of Bologna.
PhD project: Application of PSMA inhibitors for PET imaging and treatment in prostate cancer.
PhD thesis: Prediction Nomogram for ^{68}Ga-PSMA-11 PET/CT in Different Clinical Settings of PSA Failure After Radical Treatment for Prostate Cancer.

November 2018 – to present: Qualified Associate Professor (Radiology, Nuclear Medicine and Radiotherapy – MED/36), released by Italian Minister of Education, University and Research (MIUR).

Current Position: December 2018 – to present

Assistant Professor, Department of Medical Sciences, University of Turin, Italy.
Consultant in Nuclear Medicine, AOU Città della Salute e della Scienza di Torino, Turin, Italy.

Professional Experience

Oct 2006 - May 2007: Nuclear Medicine, Klinikum Recht der Isar – Technischen Universität München (TUM), Germany

Position: Undergraduate Assistant Researcher

Research project: Fusion of a recombinant antibody fragment with a homo-amino-acid polymer: effects on biophysical properties and prolonged plasma half-life

May 2007 - July 2007: Nuclear Medicine, Klinikum Grosshadern and Innestadt Klinikum – Ludwig Maximilian Universität München, Germany

Position: Visiting Undergraduate Fellow

Sept 2007 - Sept 2009: Nuclear Medicine, S.Orsola-Malpighi Hospital – Alma Mater Studiorum University of Bologna, Italy

Position: Undergraduate Assistant Researcher

Research project: ^{18}F-FDG small animal PET to evaluate Sorafenib efficacy in murine xenograft models of lymphoma.

Feb 2010 - Mar 2010: Nuclear Medicine/Clinical Physiology Unit and Haematology Unit, Rigshospitalet Copenhagen, Denmark

Position: Visiting Postgraduate Fellow

Sept 2010 - Dec 2010: Nuclear Medicine and Radiology, Wolfson Molecular Imaging Centre – University of Manchester, United Kingdom

Position: Visiting Postgraduate Fellow

Jun 2011 – Jun 2016: Nuclear Medicine – S.Orsola Malpighi Hospital – Alma Mater Studiorum University of Bologna, Italy

Position: Resident Physician

Oct 2013 - Dec 2013: Nuclaer Medicine, Uniklinikum Würzburg – Universitätsklinikum Würzburg, Germany

Position: Resident Physician / Visiting Researcher

Project: Clinical Impact of ^{11}C-Choline PET/CT in recurrent prostate cancer patients after radical therapy.

May 2014 - June 2014 and Oct 2014 - Dec 2014: Nuclear Medicine – Universitätsklinikum Innsbruck, Austria

Position: Resident Physician / Visiting Researcher

Project: ^{68}Ga-PSMA-PET/CT in recurrent prostate cancer patients

July 2016 – June 2017: Nuclear Medicine, PET center – S.Orsola Malpighi University Hospital of Bologna, Italy

Position: PET/CT reader.

June 2017 – December 2018: Department of Molecular and Medical Pharmacology – Nuclear Medicine UCLA Medical Center and Ahmanson Translational Imaging Division, University of California Los Angeles (UCLA)

Position: Visiting Assistant Professor

Research Experience

Publications (reported in detail in the attached document)

Author of 66 scientific peer-reviewed publications in international journals indexed on PubMed, MEDLINE, SCOPUS.

Author of 3 book chapters edited by Springer International Publishing.

Authors of 67 abstract presented in international congresses of nuclear medicine, urology and oncology.

H-index: Scopus, 18; Google Scholar, 19.

Citation index: Scopus, 1153; Google Scholar, 1569.

On-going Research activity:

- PSMA PET imaging in Prostate Cancer (University of Turin). Role: PI.
- Radiomics and Texture Analysis for PET imaging in oncology (University of Turin). Role: Co-PI.
- Radio-guided Surgery in Prostate Cancer (University of Turin). Role: Co-PI.
- FDG-PET imaging in advanced non-small cells lung cancer (NSCLC), treated with PD-1 and PD-L1 inhibitors (University of Turin). Role: PI.
- Somatostatin-agonist PET imaging in Neuroendocrine Tumors (University of Turin). Role: Co-PI.
- Prediction Models for PET imaging in Prostate Cancer (Multicenter International Study). Role: PI.

- PSMA PET imaging to stage intermediate-risk and high-risk Prostate Cancer prior to radical prostatectomy (University of California Los Angeles, University of San Francisco). Role: sub-investigator.
- Guidelines and standardization of interpretation criteria for PSMA PET imaging in prostate cancer (European Association of Nuclear Medicine, EANM). Role: PI.

Clinical Experience

More than eight years' experience in PET/CT images reading, with FDG and non-FDG radiotracers (including, ^{18}F-FDG, ^{68}Ga-PSMA, ^{11}C-Choline, ^{18}F-fluciclovine, ^{68}Ga-DOTA-SSR ligand peptides, ^{11}C-Methionine, ^{18}F-FLT, ^{64}Cu-ATSM, ^{18}F-NaF, ^{18}F-DOPA, ^{18}F-FET, ^{11}C-Acetate, ^{11}C-Ephedrine).

More than three years' experience in radioligand therapy in nuclear medicine, with I-131, 177-Lu-DOTA-TOC, 90Y-DOTA-TOC, 177Lu-PSMA-617, 223-$RaCl_2$.

Teaching and Academic Experience

June 2011 to June 2016: clinical tutoring to medical students (Nuclear Medicine - School of Medicine, University of Bologna, Italy).
Lecturer to Oncology, Radiology and Radiotherapy Residency Program (University of Bologna, Italy).

April 2017 to present: facilitator, lecturer and board member of the European School of Multimodality Imaging and Therapy (ESMIT) of the European Association of Nuclear Medicine (EANM).

December 2018 to present: lecturer and tenure of "Radiology and Molecular Imaging" class (MED/36) – School of Medicine, University of Turin, Italy.
Lecturer and tenure of "In Vivo Imaging" class – Biotechnology (BIO/10), University of Turin, Italy.
Lecturer and coordinator of the School of Nuclear Medicine (Residency Program), University of Turin, Italy
Lecturer of the Radiology and Radiotherapy Residency Program
Supervisor for medical doctor (MD) thesis and Supervisor for Nuclear Medicine Residency Program thesis - University of Turin, Italy.

September 2019 – to present: facilitator and lecturer of SiUro (Italian Society of Urologic Oncology).

Participation to international congress and meetings

He attended and submitted abstracts to the main congresses in Nuclear Medicine (EANM, SNMMI, AIMN), Urology (EAU, EMUC, ESUI and AUA) and Oncology (ASCO) since 2009 to present. Selected as speaker for "oral presentation" to EANM congress from 2012 to 2019, to SNMMI in 2014 and 2019 and EAU 2019. Moderator at SNMMI annual conference in 2019.

Invited Lectures

Invited 43 times as honourable speaker and lecturer to national and international conferences, mainly focusing on PET imaging, theranostics and prostate cancer.

Honours and Awards

April 2016: "Rudolf-Hoefer Award" – Best Austrian scientific publication on radioactive isotopes in clinical research.

Article: ^{68}Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?

(April 26th 2016, Wien, Austria)

October 2016: winner of "EANM Eckert & Ziegler Abstract Award 2016" - Abstract Competition at the Annual Congress of the European Association of Nuclear Medicine.

Abstract: ^{68}Ga-PSMA PET/CT for early restaging prostate cancer. Preliminary results of a prospective trial in patients with biochemical failure after radical therapy and PSA levels < 2ng/mL.

(October 19th 2016, Barcelona, Spain)

October 2016: nominated for "Marie Curie Award 2016" – Best contribution at the annual EANM Congress of the European Association of Nuclear Medicine.

Abstract: 68Ga-PSMA PET/CT for early restaging prostate cancer. Preliminary results of a prospective trial in patients with biochemical failure after radical therapy and PSA levels < 2ng/mL.

(October 19th 2016, Barcelona, Spain)

October 2017: nominated for "Marie Curie Award 2017" – Best contribution at the annual EANM Congress of the European Association of Nuclear Medicine.

Abstract: ^{68}Ga-PSMA PET/CT to restage prostate cancer after radical therapy. Results of a prospective single-center trial.

(October 22nd 2017, Vienna, Austria)

Funded Grants Application

December 2017: "Post-doctoral Fellowship 2018". Research grant for medical researcher in oncology, promoted by "Fondazione Umberto Veronesi" (Milan, Italy).

Project title: Radiolabeled prostate-specific membrane antigen (PSMA) for diagnosis and treatment of prostate cancer.

Hosting Institute: University of California Los Angeles (UCLA).

Total amount granted: 15,000 euro.

December 2017: Ricerca Finalizzata 2016 - National Grant founded by Italian Ministry of Health. Principal Investigator: Stefano Fanti, Nuclear Medicine, S.Orsola-Malpighi Hospital, Bologna. Project: PET/CT imaging for evaluating early response to novel androgen receptor targeted agents in castration resistant prostate cancer patients. Position: Sub-investigator

Total amount granted: 333,666 euro.

March 2019: CRT Foundation – Radiomics in Neuroendocrine Tumors investigated with 68Ga-DOTA-TOC PET/CT. Principal Investigator: Desiree Deandreis, Nucelar Medicine, AOU Città della Salute e della Scienza di Torino. Position: Co-PI

Total amount granted: 68,400 euro.

Reviewer for grant applications

March 2016: reviewer for the "grant funding on prostate cancer" promoted by "Kom op Tegen Kanker Foundation", Belgium

April 2018 – to present: reviewer for REPRISE (Register of Scientific Experts) for Italian Minister of Education, University and Research (MIUR) regarding Applied Research.

Editorial Activities

- BioMedical Central Cancer Journal (BMC Cancer), Impact Factor 2.933
  Position: Associate Editor (2015 – to present)
- Journal of Nuclear Medicine (JNM), Impact Factor 7.354
  Position: Editorial Board Member (2019 – to present)
- European Journal of Nuclear Medicine (EJNMMI), Impact Factor 7.277
  Position: Editorial Board Member (2020 – to present)
- Reviewer for: European Urology Journal (Eur Urol), European Journal of Nuclear Medicine and Molecular Imaging (Eur J Nucl Med Mol Imaging), Journal of Nuclear Medicine (J Nucl Med), Journal of Urology (J Urol), Oncotarget (Oncotarget), Journal of Theranostics (Ther), European Journal of Nuclear Medicine and Molecular Imaging Research (EJNMMI Res), Asia-Pacific Journal of Clinical Oncology (APJCO), Biomedical Central Cancer Journal (BMC Cancer).
- Abstract reviewer of the European Association of Nuclear Medicine (EANM) for the annual meeting. Abstract reviewer of the European Society for Molecular Imaging (EMIM) for the annual meeting.

Associations Membership

- European School of Multimodality Imaging and Therapy (ESMIT), by EANM
  Position: Faculty member and member/coordinator of the Prostate Cancer Group and Thyroid Group. Member of Case Task Force group. Facilitator and lecturer for Level 2 and Level 3 courses (2017 – to present).
- European Association of Urology (EAU)
  Position: Member (2020 – to present).
- European Association of Nuclear Medicine (EANM)
  Position: Member (2016 – to present).
- Society of Nuclear Medicine and Molecular Imaging (SNMMI)
  Position: Member (2019 – to present).
- Italian Association of Nuclear Medicine (AIMN)
  Position: Member (2019 – to present).

Research Interest

New diagnostic approaches in oncology; Development of new PET tracers in oncology; PET imaging for monitoring response to systemic therapy or metastasis directed therapy in oncology; Radioligand therapy (RLT) in oncology; Radio-guided surgery in prostate cancer; Application of radiomics, artificial intelligence and machine learning in PET imaging; Use of nano-particles as theranostic agents.

Languages

Italian (mother tongue)

English (advanced C1. IELTS Test)

German (basic A2)

Torino, January 24th 2020



(Francesco Ceci, MD PhD)